ZFNs are engineered forms of zinc finger DNA-binding proteins that also contain a nuclease component, which can induce modification of a target gene of interest
Edward Lanphier, president and CEO of Sangamo, said: “Under this second non-exclusive, research and commercial license agreement, Sangamo will design and engineer additional ZFNs that target genes identified by Genentech to potentially improve protein pharmaceutical production in mammalian cells. This further agreement strengthens our belief that there is a growing appreciation of the value of our technology which provides a rapid, reliable and highly specific method to efficiently alter genes in eukaryotic cells.”